MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Zosano Pharma Corp. Company Profile (NASDAQ:ZSAN)

Consensus Ratings for Zosano Pharma Corp. (NASDAQ:ZSAN) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $11.00 (797.59% upside)

Analysts' Ratings History for Zosano Pharma Corp. (NASDAQ:ZSAN)
Show:
DateFirmActionRatingPrice TargetActions
11/11/2015Roth CapitalBoost Price TargetBuy$7.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/5/2015Ladenburg ThalmannInitiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/2/2014 forward)
Earnings History for Zosano Pharma Corp. (NASDAQ:ZSAN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q1($0.56)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/29/2016Q4($0.67)($0.64)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.61)($0.72)$380.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.53)($0.63)$1.78 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/25/2015($0.64)($1.10)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Zosano Pharma Corp. (NASDAQ:ZSAN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.54)($0.54)($0.54)
Q2 20161($0.52)($0.52)($0.52)
Q3 20161($0.63)($0.63)($0.63)
Q4 20161($0.61)($0.61)($0.61)
(Data provided by Zacks Investment Research)
Dividend History for Zosano Pharma Corp. (NASDAQ:ZSAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Zosano Pharma Corp. (NASDAQ:ZSAN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/30/2015Enterprise Associates 12 NewMajor ShareholderBuy23,457$11.00$258,027.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Zosano Pharma Corp. (NASDAQ:ZSAN)
DateHeadline
06/29/16 07:21 PMInvestor News: Investigation for Investors in shares of Zosano Pharma Corp (NASDAQ:ZSAN) announced
06/28/16 12:31 PM10 Biggest Mid-Day Gainers For Tuesday -   ReachLocal Inc. (NASDAQ: RLOC) shares jumped 169 percent to $4.55 after Gannett Co Inc (NYSE: GCI) announced its plans to acquire the company for $4.60 per share. New Concept Energy, Inc. (NYSE: GBR) shares rose 71 percent to $2.36. Zosano Pharma Corp (NASDAQ: ZSAN) shares climbed 66 percent to $1.85. Xencor Inc (NASDAQ: XNCR) shares surged 36.5 percent to $17.11 after the company announced strategic collaboration ...Full story available on Benzinga.com
06/23/16 12:39 PMZOSANO ALERT: Lundin Law PC Announces an Investigation of Zosano Pharma Corporation and Advises Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / June 23, 2016 / Lundin Law PC announces it is investigating claims against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) concerning ...
06/21/16 06:50 PMInvestigation for Investors in Shares of Zosano Pharma Corp (NASDAQ:ZSAN) Announced
06/20/16 08:45 AMCERS Gets BARDA Funding, EPZM Abuzz, ZSAN Awaits Data In Q1 2017
06/20/16 08:45 AMZosano Pharma (ZSAN) Announces Enrollment of First Subject in Trial for ZP-Triptan Patch Program to Treat Migraine
06/17/16 10:08 AMZosano Pharma's pivotal study of ZP-Triptan patch for migraine underway
06/17/16 09:19 AMZosano Pharma Enrolls First Subject in Pivotal Clinical Trial for ZP-Triptan Patch Program for Treatment of Migraine - [at noodls] - FREMONT, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, ...
06/15/16 05:50 PMZOSANO INVESTIGATION ALERT: Khang & Khang LLP Announces An Ongoing Investigation of Claims against Zosano Pharma Corporation And Encourages Investors With Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / June 15, 2016 / Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Zosano Pharma Corporation ("Zosano" or the "Company") ...
06/14/16 12:52 PMONGOING INVESTIGATION: Lundin Law PC Announces Investigation of Zosano Pharma Corporation and Advises Investors with Losses to Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / June 14, 2016 / Lundin Law PC announces it is investigating claims against Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) concerning ...
05/20/16 04:03 PMEdited Transcript of ZSAN earnings conference call or presentation 12-May-16 8:30pm GMT -
05/20/16 12:04 PMZOSANO PHARMA CORP Financials -
05/17/16 11:20 AMINVESTIGATION ALERT: Khang & Khang LLP Announces An Ongoing Investigation of Claims against Zosano Pharma Corporation And Encourages Investors With Losses to Contact the Firm - [Accesswire] - IRVINE, CA / ACCESSWIRE / May 17, 2016 / Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Zosano Pharma Corporation ("Zosano" or the "Company") ...
05/17/16 10:58 AMSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zosano Pharma Corporation (ZSAN) - [PR Newswire] - NEW YORK, May 17, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Zosano Pharma Corporation ...
05/16/16 05:50 PMSHAREHOLDER ALERT: Lundin Law PC Announces Investigation Of Zosano Pharma Corporation And Advises Investors With Losses To Contact the Firm - [Accesswire] - LOS ANGELES, CA / ACCESSWIRE / May 16, 2016 / Lundin Law PC announces it is investigating claims against Zosano Pharma Corporation ("Zosano" or the "Company") (Nasdaq: ZSAN) concerning ...
05/12/16 04:27 PMZosano Pharma Reports First Quarter 2016 Financial Results - [at noodls] - FREMONT, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, ...
05/12/16 03:59 PMINVESTOR ALERT: Investigation of Zosano Pharma Corporation Announced by the Law Firm Goldman Scarlato & Penny, P.C.; Investors Encouraged to Contact the Firm - [Business Wire] - Goldman Scarlato & Penny, P.C. announces an investigation on behalf of shareholders of Zosano Pharma Corporation concerning potential violations of the federal securities laws by the Company and company insiders.
05/12/16 03:14 PMZOSANO PHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi -
05/12/16 06:07 AMQ1 2016 Zosano Pharma Corp Earnings Release - Time Not Supplied -
05/09/16 07:38 AMZosano Announces Appointment of John P. Walker as Chairman of the Board - [at noodls] - FREMONT, Calif., May 09, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical stage specialty pharmaceutical company with proprietary technology for the dermal delivery of drugs, ...
05/02/16 03:30 PMZosano Pharma to Report First Quarter 2016 Financial Results - [at noodls] - FREMONT, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN) today announced that it plans to report financial results for the first quarter of 2016 on Thursday, May 12, 2016. ...
02/26/16 01:35 PMTrading Report: Gaps Up – Zosano Pharma (ZSAN), CafePress (PRSS), Ultra Clean (UCTT) - Zosano Pharma Corp (ZSAN) had a gap up of (0.03) pts or -1.39 pct above its previous close of $2.16. The company traded at $2.39 + 0.2299 (10.64 pct). CafePress Inc. (PRSS) had a gap up of 0.35 pts or 10.20 pct above its previous close of $3.43.
02/09/16 02:39 PMINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Zosano Pharma Corporation -- ZSAN - [PR Newswire] - NEW YORK, Feb. 9, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Zosano Pharma Corporation (NASDAQCM: ZSAN) concerning possible violations of federal securities laws ...
02/09/16 10:55 AMSHAREHOLDER NOTICE: Khang & Khang LLP Announces an Ongoing Investigation of Claims against Zosano Pharma Corporation and Encourages Investors With Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Zosano Pharma Corporation . The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
02/09/16 08:06 AMZOSANO PHARMA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Continues its Investigation of Zosano Pharma Corporation; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights - [Business Wire] - Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Zosano Pharma Corporation and certain of its officers and directors.
02/04/16 03:15 PMZOSANO PHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
01/27/16 03:08 PMZOSANO PHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers -
01/21/16 05:27 PMIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces an Ongoing Investigation of Claims against Zosano Pharma Corporation and Encourages Investors With Losses to Contact the Firm - [Business Wire] - Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by Zosano Pharma Corporation . The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors.
01/21/16 12:14 PMHarwood Feffer LLP Announces Investigation of Zosano Pharma Corporation - [PR Newswire] - NEW YORK, Jan. 21, 2016 /PRNewswire/ -- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential claims against the board of directors of Zosano Pharma Corporation ("Zosano" or the "Company") ...
01/21/16 10:40 AMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of Zosano Pharma Corporation - [Business Wire] - Levi & Korsinsky announces it has commenced an investigation of Zosano Pharma Corporation concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
01/20/16 03:19 PMRobbins Arroyo LLP Is Investigating the Officers and Directors of Zosano Pharma Corporation (ZSAN) on Behalf of Shareholders - [Business Wire] - Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Zosano Pharma Corporation violated federal securities laws by issuing materially misleading business information to the investing public.
01/07/16 04:13 PMZOSANO PHARMA CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements -
01/06/16 09:31 PMZOSANO PHARMA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Zosano Pharma Corporation; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights - [Business Wire] - California-based Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Zosano Pharma Corporation and certain of its officers and directors.
About Zosano Pharma Corp.

Zosano Pharma Corp. logoZosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers rapid onset, consistent drug delivery and improved ease of use and room-temperature stability. Its microneedle patch system has the potential to deliver numerous medications for a range of indications in commercially attractive markets. The Company's short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an existing drug and attached to an adhesive patch. Its lead product candidates, and the indications they are expected to treat include Daily ZP-PTH, for severe osteoporosis; ZP-Glucagon, for severe hypoglycemia, and ZP-Triptan, for migraine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZSAN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.23
  • 50 Day Moving Average: $1.6272
  • 200 Day Moving Average: $2.1202
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $14.72M
  • Current Quarter EPS Consensus Estimate: $-2.3000 EPS
Additional Links:
Zosano Pharma Corp. (NASDAQ:ZSAN) Chart for Saturday, July, 2, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha